[ad_1]

The trial investigated the effect of Jardiance on all-cause mortality and hospitalization in patients after a heart attack. Credit: Ahmet Misirligul / Shutterstock.com.

Boehringer Ingelheim and Eli Lilly reported data from the Phase III EMPACT-MI clinical trial of Jardiance (empagliflozin) on the risk of heart failure hospitalization and mortality after a heart attack.

A randomized, multicenter, parallel-group, double-blind, placebo-controlled superiority trial investigated the Jardiance on all-cause mortality and hospitalization in such patients.

The study included more than 6,500 adult patients from 22 countries who were randomly assigned to receive either Jardiance 10mg or a placebo daily in addition to standard treatment.

Participants without a history of chronic heart failure were eligible to participate regardless of type 2 diabetes or chronic kidney disease status.

A composite measure of time to first hospitalization for heart failure or all-cause mortality up to 26 months was the study’s primary endpoint.

Results from the EMPACT-MI trial were reported in partnership with Duke Clinical Research Institute (DCRI) and funded by Boehringer Ingelheim and Lilly.

Access the most comprehensive company profiles on the market with GlobalData. Save research time. Increase competitiveness.

Company Profile – Free Sample

You will receive a download email shortly

We are confident in the unique quality of our company profile. However, we want you to make the decision that is most beneficial for your business, so we are offering free samples that you can download by submitting the form below.

by global data







For more information about our services and how we use, process and share your personal data, including information about your rights regarding your personal data and how to unsubscribe from future marketing communications, please see our Privacy Policy Please refer to the. Our service is intended for corporate subscribers and we guarantee that the email address you submit is a corporate email address.

Data revealed a 10% relative risk reduction in the primary composite endpoint for participants treated with Jardiance compared to placebo, but did not reach statistical significance. did.

Further exploratory analyzes showed a 23% relative reduction in time to first hospitalization for heart failure and a 33% relative reduction in risk of total hospitalization for heart failure with Jardiance compared to placebo. Ta.

said Mohamed Eid, Vice President, Cardiac, Renal and Metabolic Medicine, Clinical Development and Medical Affairs, Boehringer Ingelheim Pharmaceuticals. “These results further deepen our understanding of SGLT2 inhibitors and contribute to a body of evidence across six clinical studies examining the potential for Jardiance to have a major impact on heart failure, chronic kidney disease, or 2 Results in a broad population of adults with type diabetes mellitus.

“Building on this strong foundation, we continue to raise awareness, generate real-world evidence, and advance treatments for people affected by relevant cardiovascular, renal, and metabolic diseases. I am committed to leading efforts to achieve this goal.”

In November 2021, the companies reported that empagliflozin reduced the risk of cardiovascular death or hospitalization for heart failure and slowed the decline in kidney function in the Phase III EMPEROR-Preserved trial.




[ad_2]

Source link